Comparative Study Convention on Clinical Effectiveness, Safety, and Economical Economy by Real-Time Quantification, Accuracy and Precision Injection with THE KOREAN SOCIETY OF NEONATOLOGY

About 170 million newborns are born every year, and about 29 million, or 17 percent, are premature, underweight and severely ill, of which about 30 percent are born in developed countries, estimated to be 10 million.

Precise medicine by precise injection of medicines and nutritional supplements prescribed on medical and clinical grounds until newborns born around the world become normal is an absolutely necessary medicine, especially for the growth and development of newborns and future health of severely ill patients.

Until now, the medical personnel's long-cherished desire has been to develop a drug injection pump that realizes precision medicine due to various problems such as inaccuracy, risk of infection, classification, and start-up delay.

In addition, to overcome these problems, real-time inspection, adjustment, and management have been performed to maintain and treat the average injection amount.

Nursing work, or work load, was added to the problem of the original technology of the existing product, resulting in an increase in medical accidents and medical expenses.

Busy work, premature babies who need high risk and concentration, low-weight children, and intensive care treatment and nursing work are accompanied by considerable work stress, and there is a very lack of skilled medical staff at high turnover.

As Anyfusion, which solves the fundamental problems of existing products and medical staff's long-cherished desire, we decided to conduct a comparative study on clinical efficacy and safety of 24 to 96-hour medicines and TPNs in real-time quantitative, accurate, and precise injections.

First of all, it is a retrospective study that compares the validity, work load, and safety with existing products by checking through demo at many hospitals, including major hospitals, and using the product directly to purchasing patients.

In addition, if its effectiveness is verified in Korea, the government will conduct a global clinical trial study that includes advanced countries such as the United States, Japan, and Germany, where government policies and systems are the top priority.

For this study, we are confident that Anyfusion will be an essential equipment for drug injection pumps in the global NICU and ICU when the product is purchased in demo, clinical efficacy, safety, work load, etc. are verified, published in SCI paper, and published in the relevant world society.

The annual market size is expected to be about 20 trillion won to more than 30 trillion won, reflecting the value of clinical effectiveness, safety, and economic feasibility due to the reduction of workload.

It will be an opportunity to lead this market.

EZ Regular, which has been sold in the U.S., Japan, and Germany for more than 17 years, has the longest Euro length and is more accurate than the existing similar products, and EZ Regular, which overcomes secondary problems such as leakage and defects due to temperature difference, will also be demoed and used.

EZ Regular is proven in developed countries where validity, safety, and low defect rate have been used for more than 17 years and is expected to change the parameters of the market along with Anyfusion.

Now, the need for high-quality products that have experienced economic losses due to the use of low-priced products and medical accidents due to high defect rates in the domestic market will serve as an opportunity to realize optimal medical effects with standard products that overcome their efficacy and safety.

Thank you.